Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atiprimod in Low to Intermediate Grade Neuroendocrine Carcinoma
NCT00388063Phase 2Completed
- Sponsor
- Callisto Pharmaceuticals, Inc.
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atiprimod in neuroendocrine carcinoma (NEC), sponsored by Callisto Pharmaceuticals, Inc. Primary endpoints: Reduction of symptoms at 1 year and Progression of neuroendocrine tumor at 1 year. Started Oct 2006; status: completed.
02
Drugs
atiprimod
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT00388063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00388063.